Types of purinoceptors and phospholipase A2 involved in the activation of the platelet-activating factor-dependent transacetylase activity and arachidonate release by ATP in endothelial cells

被引:9
作者
Balestrieri, ML
Malik, KU
Balestrieri, C
Lee, TC
机构
[1] Oak Ridge Associated Univ, Environm & Hlth Sci Div, Oak Ridge, TN 37831 USA
[2] Univ Naples 2, Dept Biochem & Biophys F Cedrangolo, I-80138 Naples, Italy
[3] Univ Tennessee, Ctr Hlth Sci, Coll Med, Dept Pharmacol, Memphis, TN 38163 USA
来源
PROSTAGLANDINS & OTHER LIPID MEDIATORS | 1998年 / 56卷 / 5-6期
关键词
purinoceptors; phospholipase A(2); platelet-activating factor; PAF-dependent transacetylase; acyl analogs of PAF; arachidonate release; endothelial cells;
D O I
10.1016/S0090-6980(98)00065-3
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Acyl analogs of PAF are the major products synthesized during agonist stimulation of endothelial cells. We have previously shown that PAF: 1-acyl-2-lyso-sn-glycero-3-phosphocholine transacetylase in calf pulmonary artery endothelial cells is activated by ATP through protein phosphorylation, and the increase in transacetylase activity by ATP contributes to the biosynthesis of acyl analogs of PAF (J. Biol. Chem. 272, 17431-17437, 1997). To understand the mechanism(s) by which ATP stimulates acyl analogs of PAF production, we have identified the subtypes of the purinergic receptor that are linked to the activation of two enzymes involved in the generation of acyl analogs of PAF, namely, transacetylase and phospholipase A(2). Experiments with transient transfection of the cells with antisense and sense thio-oligonucleotide to cytosolic phospholipase A(2) (cPLA(2)) were also performed to evaluate whether downstream activation of cPLA(2) is involved in ATP-receptor mediated induction of arachidonate release and synthesis of radylacetyl-GPC. We found that the P-2u/P2Y(2) receptor, which recognizes a pyrimidine nucleotide, UTP, as well as purine nucleotides, shows a potency profile of UTP > ATP = ATP gamma S > 2-methylthio-ATP in mediating the activation of PAF: lysophospholipid transacetylase, On the other hand, ADP beta S and 2-methylthio-ATP have similar potencies as ATP but have lower potencies than UTP and ATP gamma S in stimulating the release of arachidonate. These results suggest that both P-2u/P2Y(2) and P-2y/P2Y(1) receptor subtypes promote arachidonate release. In addition, transient transfection of endothelial cells with cPLA(2) antisense but not the sense thio-oligonucleotide inhibited the stimulation of arachidonate release and [H-3]acetate incorporation into radyl[H-3]acetyl-GPC. Thus, our data suggest that a receptor-mediated process is involved in the activation of transacetylase for the induced synthesis of acyl analogs of PAF in endothelial cells. Furthermore, it is Likely that cPLA(2) supplies the lysophospholipids as substrates for the transacetylation reaction.
引用
收藏
页码:363 / 375
页数:13
相关论文
共 35 条
  • [1] The role of platelet-activating factor-dependent transacetylase in the biosynthesis of 1-acyl-2-acetyl-sn-glycero-3-phosphocholine by stimulated endothelial cells
    Balestrieri, ML
    Servillo, L
    Lee, TC
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (28) : 17431 - 17437
  • [2] Leukotriene B-4 and platelet activating factor production in permeabilized human neutrophils: Role of cytosolic PLA(2) in LTB(4) and PAF generation
    Bauldry, SA
    Wooten, RE
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-LIPIDS AND LIPID METABOLISM, 1996, 1303 (01): : 63 - 73
  • [3] Burnstock G, 1996, DRUG DEVELOP RES, V38, P67, DOI 10.1002/(SICI)1098-2299(199605)38:1<67::AID-DDR9>3.0.CO
  • [4] 2-J
  • [5] PLATELET-ACTIVATING-FACTOR - RECEPTORS AND SIGNAL-TRANSDUCTION
    CHAO, W
    OLSON, MS
    [J]. BIOCHEMICAL JOURNAL, 1993, 292 : 617 - 629
  • [6] Heterogeneity of P-2u- and P-2y-purinergic receptor regulation of phospholipases in MDCK cells
    Firestein, BL
    Xing, MZ
    Hughes, RJ
    Corvera, CU
    Insel, PA
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-RENAL FLUID AND ELECTROLYTE PHYSIOLOGY, 1996, 271 (03): : F610 - F618
  • [7] FREDHOLM BB, 1994, PHARMACOL REV, V46, P143
  • [8] HARDEN TK, 1995, ANNU REV PHARMACOL, V35, P541, DOI 10.1146/annurev.pa.35.040195.002545
  • [9] HOLLAND MR, 1992, J BIOL CHEM, V267, P22883
  • [10] Kan H, 1996, MOL PHARMACOL, V50, P1139